Research programme: SN 38 immunoconjugates - Immunomedics

Drug Profile

Research programme: SN 38 immunoconjugates - Immunomedics

Alternative Names: Antibody-SN-38 conjugates; CD74-targeted milatuzumab-SN 38 immunoconjugates; Epratuzumab-SN 38; hA20-SN 38; hL243-SN-38; hLL2-SN 38; hPAM4-SN 38; IMMU-114-SN-38; milatuzumab-CL2A-SN 38; milatuzumab-CL2E-SN 38; Milatuzumab-SN 38

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Immunomedics
  • Class Camptothecins; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Haematological malignancies; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Jan 2016 Immunomedics has patent protection for the use of SN 38 immunoconjugates combination in USA
  • 18 Aug 2015 Immunomedics has patent protection for SN-38 immunoconjugates with a CL2A linker in USA
  • 27 Jun 2012 Immunomedics plans a phase I trial of its hRS7-SN38 antibody drug conjugate in advanced epithelial cancers in the US (NCT01631552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top